Sponsors (6)
The bill injects substantial, targeted public capital and administrative capacity into commercializing critical technologies—especially biotech—while speeding program startup, but it increases taxpayer exposure and concentrates decision-making power with reduced public oversight and some risks of market distortion.
Scientists, biotech firms, and small tech businesses receive immediate, dedicated funding (including $300M for biotech in FY2025 and $975.5M total for FY2025) enabling R&D, commercialization, and initial program launch.
Startup founders, early employees, and private investors gain targeted seed-to-mid-stage capital ($1M–$10M typical) and clearer federal technology priorities, improving chances to commercialize critical technologies and attracting private co-investment.
Portfolio companies and U.S. technology projects are better insulated from adversarial influence because the Fund bars investments with foreign entities of concern and ties covered technologies to an NSTC-maintained list.
Taxpayers face substantial near-term and potential future fiscal exposure—about $975.5M new spending in FY2025 plus conditional supplemental authorizations (up to $500M later) and the risk that Fund investments may lose money.
The Act reduces public oversight and input by exempting advisory boards from FACA, declaring the Fund not a federal agency, and carving out Paperwork Reduction/APA processes—limiting transparency, notice-and-comment, and external scrutiny.
Broad statutory definitions (e.g., of covered technologies, 'adversarial investment,' and 'other transactions') and delegation to NSTC/executive bodies could expand the Fund's scope unpredictably and reduce direct congressional control over what technologies are covered.
Based on analysis of 8 sections of legislative text.
Introduced December 3, 2025 by Pete Sessions · Last progress December 3, 2025
Creates a Treasury-managed Independence Investment Fund to make seed-to-mid-stage equity investments in U.S.-headquartered technology companies (with a priority on biotechnology) that advance U.S. national and economic security. The Fund will be run by an independent managing entity chosen by open competition, overseen by advisory and supervisory boards, exempt from certain federal rulemaking and paperwork laws, staffed with up to 25 special-pay employees, and supported by nearly $1.0 billion in initial authorized funding plus recurring operating authorizations and conditional supplemental biotech funding through 2040.